Trials / Terminated
TerminatedNCT03890120
Study of Cilofexor in Adults With Primary Sclerosing Cholangitis
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 419 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate whether cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cilofexor | 100 mg tablet administered orally once daily |
| DRUG | Placebo | Tablet administered orally once daily |
Timeline
- Start date
- 2019-03-27
- Primary completion
- 2022-11-10
- Completion
- 2022-12-23
- First posted
- 2019-03-26
- Last updated
- 2023-11-29
- Results posted
- 2023-11-29
Locations
201 sites across 16 countries: United States, Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Israel, Italy, Japan, New Zealand, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03890120. Inclusion in this directory is not an endorsement.